Atomoxetine

Drug Profile

Atomoxetine

Alternative Names: Atomoxetine hydrochloride; LY 139603; Strattera; Tomoxetine; Tomoxetine hydrochloride

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Johns Hopkins University
  • Class Propylamines
  • Mechanism of Action Adrenergic uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder
  • Phase III Parkinson's disease
  • Discontinued Alzheimer's disease; Major depressive disorder

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Attention-deficit-hyperactivity-disorder(In volunteers) in Japan (PO, Liquid)
  • 15 Mar 2016 Biomarkers information updated
  • 07 Aug 2015 No recent reports on development identified - Phase-III for Attention-deficit hyperactivity disorder (In adults) in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top